reviewJournal of Hematology & OncologyDec 1, 2019GOLD OA

LSD1/KDM1A inhibitors in clinical trials: advances and prospects

YFYuan FangGLGuochao LiaoBYBin Yu

Guangzhou University of Chinese Medicine · Ministry of Education of the People's Republic of China · +3 more institutions

PubMed
Indexed incrossrefdoajpubmed

Abstract

Histone demethylase LSD1 plays key roles during carcinogenesis, targeting LSD1 is becoming an emerging option for the treatment of cancers. Numerous LSD1 inhibitors have been reported to date, some of them such as TCP, ORY-1001, GSK-2879552, IMG-7289, INCB059872, CC-90011, and ORY-2001 currently undergo clinical assessment for cancer therapy, particularly for small lung cancer cells (SCLC) and acute myeloid leukemia (AML). This review is to provide a comprehensive overview of LSD1 inhibitors in clinical trials including molecular mechanistic studies, clinical efficacy, adverse drug reactions, and PD/PK studies and offer prospects in this field.

Citation impact

447
total citations
FWCI
15.72
Percentile
100%
References
126
Citations per year

Authors

3

Topics & keywords

Topics
Keywords
  • Medicine
  • Hematology
  • Clinical trial
  • Internal medicine
  • Medical physics
  • Intensive care medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding